John Frederick Ek - 22 Feb 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role: CFO
Signature: /s/ John Frederick Ek, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol: AKYA
Transactions as of: 22 Feb 2024
Transactions value $: $0
Form type: 4
Filing time: 01 Mar 2024, 21:58:27
Previous filing: 12 Jun 2023
Next filing: 02 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKYA	Common Stock	Award	$0	+35K	+21.88%	$0.00	195K	22 Feb 2024	Direct	F1, F2
holding	AKYA	Common Stock						20K	22 Feb 2024	Ek Trust Dated November 20, 2020

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKYA	Employee Stock Option (Right to Buy)	Award	$0	+70K		$0.00	70K	22 Feb 2024	Common Stock	70K	$5.35	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
F2	Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
F3	The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.